Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Treatment plan and informed consent].

K Ozawa1

  • 1Department of Medicine, Division of Hematology, Jichi Medical School.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 5, 2002
PubMed
Summary

STI571 is now the primary treatment for chronic myeloid leukemia (CML). Allogeneic stem cell transplantation (SCT) is recommended for eligible patients, while others may require combination therapy for optimal outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acquisition of interleukin-3 independence in FDC-P2 cells after transfection with the activated c-H-ras gene using a bovine papillomavirus-based plasmid vector.

Blood·1992
Same author

Adult T-cell leukemia developing during immunosuppressive treatment in a renal transplant recipient.

American journal of hematology·1992
Same author

An increase in spontaneous proliferation of peripheral blood mononuclear cells in the early phase after liver transplantation--a useful indication of acute rejection.

Transplantation·1992
Same author

[A case of spontaneous mediastinal emphysema developed by numbness of the left arm, dysphagia and chest pain].

Kokyu to junkan. Respiration & circulation·1992
Same author

An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors.

Annals of surgery·1992
Same author

Tolerance of the liver as measured by ketone body ratio and hepatocyte energy charge to 120 minutes acute venous congestion in dogs.

Circulatory shock·1992

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Context:

  • Chronic myeloid leukemia (CML) management has evolved with the advent of targeted therapies.
  • Interferon-alpha (IFN-alpha) is being superseded by STI571 (imatinib mesylate) for CML treatment.
  • Advances in allogeneic hematopoietic stem cell transplantation (SCT), including mini-transplant and cord blood transplantation, offer alternative strategies.

Purpose:

  • To re-evaluate the treatment protocol for chronic phase CML in light of STI571's efficacy and limitations.
  • To outline current recommendations for newly-diagnosed CML patients.
  • To discuss alternative therapeutic approaches for patients refractory to STI571 or ineligible for SCT.

Summary:

  • Newly-diagnosed chronic phase CML patients should initiate treatment with STI571.
  • Allogeneic SCT is recommended within one year for eligible patients with HLA-identical sibling donors.
  • For patients refractory to STI571 or ineligible for SCT, combination therapies including IFN-alpha and/or chemotherapy are considered.

Impact:

  • STI571 represents a significant therapeutic advance, potentially replacing IFN-alpha in CML management.
  • The study highlights the importance of considering allogeneic SCT for long-term survival in CML.
  • Individualized treatment planning, considering risks and benefits of each modality, is crucial for optimal patient outcomes.

Related Experiment Videos